The dopaminergic system has been implicated in the aetiology of mood disorders. We conducted family-based association studies for polymorphisms at three genes involved in the metabolism of dopamine: dopamine transporter (DAT1), dopamine-␤-hydroxylase (DBH) and catechol-O-methyl transferase (COMT); and three dopamine receptors: DRD2, DRD3 and DRD5. We used a sample of 122 parent-offspring trios of British Caucasian origin where the proband had bipolar disorder I (BPI), and analysed the results with the transmission/disequilibrium test (TDT) which is robust to hidden population stratification. No statistically significant differences were found between transmitted and not transmitted alleles for any of the polymorphisms studied.
Introduction
Bipolar affective disorder (BP), also known as manic depression, is a common disorder affecting ෂ0.8% of the general population. It presents with episodes of mania and depression, although an episode of mania alone is sufficient for the diagnosis. The major genetic contribution to MDI has been shown by family, twin and adoption studies. 1, 2 However, the mode of inheritance, like that of other common disorders, is complex and non-Mendelian. The transmission in the majority of cases probably involves the interaction of several (perhaps many) genes together with environmental factors. 3 Linkage studies using the lod-score method have so far failed to provide definitive evidence for location of a gene for MDI. This method may fail to detect genes in disorders of complex inheritance because they do not show clear-cut Mendelian transmission. 4 Association studies may be more effective than linkage as a strategy to identify disease loci of modest effect. 5 Several lines of evidence implicate the dopaminergic system in the pathogenesis of both manic and depressive episodes. Dopaminergic drugs such as amphetamines and l-DOPA can provoke manic episodes in susceptible individuals. 6, 7 Antipsychotic drugs Correspondence: Dr G Kirov, Neuropsychiatric Genetics Unit, Divisions of Psychological Medicine and Medical Genetics, Tenovus Building, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, UK. E-mail: kirovȰcardiff.ac.uk Received 9 February 1999; revised and accepted 15 April 1999 (neuroleptics) which are dopamine antagonists are very effective in the treatment of mania and can also induce depression. 8, 9 Dopamine is likely to be contributing significantly to the pathophysiology of depression and increases in dopaminergic function have been consistently found after long-term treatment with antidepressants. 10, 11 Dopaminergic drugs can be used to augment the action of antidepressants in patients with treatment-resistant depressive disorders. 12 This makes the genes involved in the metabolism of dopamine and those encoding dopamine receptors important candidates for investigation in BP. In this paper we present our investigations on associations between BPI and polymorphisms at six such genes. Polymorphisms of potential functional relevance were chosen wherever available. Previous linkage and association studies of these polymorphisms in BP are reviewed in the Discussion section.
The dopamine transporter (DAT1)
The dopamine transporter (DAT) plays a key role in the regulation of dopaminergic neurotransmission by mediating the active reuptake of synaptic dopamine. Amphetamines act on the dopamine transporter to increase synaptic dopamine. 13 This makes the dopamine transporter locus (DAT1) a good candidate gene to examine in BP. The gene encoding DAT1 has been cloned and located on chromosome 5p15.3. A 40-bp variable number tandem repeat (VNTR) in the 3Ј untranslated region of the gene ranging from 3-11 cop-ies has been described 14 and has been the focus for most association studies on this gene.
Dopamine-␤-hydroxylase (DBH)
The enzyme D␤H catalyses the conversion of dopamine to norepinephrine. The gene encoding D␤H (at 9q34, locus symbol DBH) is the major gene encoding serum D␤H activity. A single base pair substitution at codon 304, in exon 5, encodes either alanine (DBH*304A) or serine (DBH*304S) 15 and there is some evidence that this polymorphism is associated with variation in D␤H activity, although the data are not consistent. 16 
Catechol-O-methyl transferase (COMT)
COMT is an enzyme involved in one of the major degradation pathways for the catecholamine neurotransmitters (dopamine, adrenaline, noradrenaline), thereby inactivating them. 17 The gene encoding for COMT is located at 22q11 and we examined a polymorphism (G → A transition at codon 108) which leads to a valine → methionine substitution. The Met allele encodes for a 3-4-fold lower activity of the enzyme 18 which makes this polymorphism an appealing candidate to study in BP.
Polymorphisms in dopamine receptor genes
Five dopamine receptors have been identified. 19 All antipsychotics block the D2 receptors but more recently the role of D3, D4 and D5 has received increasing attention. D2 is mainly localised in the basal ganglia, while D3, D4 and D5 are found mainly in the cortical and limbic regions. 19 We examined suitable polymorphisms in D2, D3 and D5 receptor genes.
DRD2
The gene maps to chromosome 11q22.3-q23 and previous intensive search for nucleotide variants causing alterations in the amino acid sequence of the gene has identified only a few rare variants. 20 We chose to examine a recently identified polymorphism in the promoter region of the gene which has been shown to alter gene expression: the −141C Ins/−141 Del.
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DRD3
The DRD3 receptor gene maps to 3q13.3. A biallelic polymorphism which gives rise to a glycine to serine substitution in the first exon of the D3 receptor gene has been extensively investigated in schizophrenic patients. It creates a BalI restriction enzyme site and interest has focused on the increased frequency of homozygosity for either allele in schizophrenic patients. 22 The polymorphism appears to be functional in that the 2-2 genotype showed significantly higher dopamine binding activity than the 1-2 and 2-2 genotypes.
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DRD5 This is a good candidate gene because it also maps to the area of chromosome 4p15.1-16.1 where strong linkage to BP was reported in a large multiply affected pedigree. 24 Linkage to the same area was reported in a family affected with schizoaffective disorder collected at our department. 25 We examined a highly polymorphic dinucleotide repeat (CT/GT/GA) n at DRD5. 26 An inherent problem with association studies which use a case-control design is the possibility that population stratification might produce false positive results. A robust way of overcoming the problem of hidden population stratification is to use the parents of probands, as suggested by Falk 29 This test has been shown to be completely robust to nonrandom mating. 29 We have genotyped the six polymorphisms listed above on a sample of such parent-offspring trios and used the TDT to analyse the results.
Methods
Population
One hundred and thirteen probands were collected through systematic screening of attenders at lithium clinics in Wales and the South and Midlands of England. In addition, nine families responded to advertisements in the press. Only white Caucasian patients of European descent were included in the study. All patients were given information and signed a consent form for participation in genetic linkage and association studies. Ethics Committee approval for genetic linkage and association studies was obtained in all local health authorities where patients were recruited.
Diagnosis was made on the basis of all available information which included a personal interview with the SCAN instrument by GK, IJ or FMcC, 30 reports from the parents and hospital records. The OPCRIT checklist 31 was completed for all probands. All diagnoses were reviewed by an independent clinician (NC) and a final consensus diagnosis according to DSM-IV was made. Only probands with BPI were included in this study. Despite the fact that most patients were recruited from lithium clinics, they were not all lithium responders as these clinics usually looked after bipolar patients who did not respond to lithium and were treated with anticonvulsants and/or depot neuroleptics.
The total sample included 122 families. There were 55 male and 67 female probands with a mean age of 33.8, SD = 8.4 years. Their fathers had a mean age of 64.2, SD = 9.7 years, and the mothers: 61.9 years, SD = 9.4 years. Because some of the genotypings were performed while the sample was being collected, and a few individuals' DNAs would not amplify well for every polymorphism studied, the reported number of families for each gene ranges from 110 to 120.
Genotyping
Standard polymerase chain reaction (PCR) in 12 l reactions was performed with any modifications listed below. Primer sequences, Mg 2+ concentrations and annealing temperatures for the genotypings are presented in Table 1 . All products except for DRD5 were separated on agarose/Metaphor gels (1.5-3% depending on the size of the products) and visualised using ethidium bromide transillumination.
DBH The polymorphism was identified by the method described in Cubells et al. 16 The G to T substitution at nucleotide position 910 results in the loss of a restriction site for MwoI (New England Biolabs, Beverly, MA, USA).
DAT1
For the PCR reaction we used Amplitaq Gold™ (Perkin Elmer, Branchburg, NJ, USA) DNA polymerase, added 5% DMSO and exchanged 50% of the dGPT with 7-deaza-guanosine.
COMT The 169-bp PCR product was digested with NlaIII restriction enzyme (New England Biolabs). The presence of a restriction site (allele 2) is associated with low enzyme activity. The method is described in Kirov et al.
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DRD2
The PCR protocol described in Arinami et al 21 was used, however we used Deep Vent DNA Polymerase. Two-step PCR was performed with initial denaturation at 98°C for 1 min, followed by 35 cycles of 98°C for 20 s and 77°C for 5 min. The 304-bp product was digested with BstN1 (New England Biolabs) which detects a restriction site at the −141C Ins allele and produces fragments of 160 and 144 bp. The restriction site is lost in the rare −141 Del allele.
DRD3
The polymorphism was detected with MscI restriction enzyme which detects the same restriction site as the BalI enzyme (New England Biolabs). The method is described in Williams et al.
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DRD5 This is a highly polymorphic dinucleotide repeat polymorphism which was detected by using fluorescently labelled primers and resolving the fragments on an ABI 373 sequencer.
Statistical analysis
For each marker we report parental and child genotype and allele frequencies, as well as the allele frequencies in the artificially constructed 'control' population which consists of the non-transmitted parental alleles. In order to test for evidence of preferential transmission of a particular allele we have used the likelihood-based Extended Transmission Disequilibrium Test (ETDT) programme 33 which can analyse multiallele marker loci. Consistency with Hardy-Weinberg equilibrium was examined on the parental genotypes using 2 goodness-of-fit tests. Power of our study using nominal test size of 0.05 was estimated for a range of allele frequencies under the assumption of a multiplicative disease model parametrized by genotype relative risks of ␥ for the heterozygote and ␥ 2 for the homozygote state of the disease-predisposing allele at the marker locus. 5, 34 Power calculations are presented in Table 2 and refer to a power of 80% to detect an association at the 0.05 level, by using the formulas proposed by Camp. 34 Using these criteria, we could expect to detect association for an allele with a frequency of 10% if it leads to a ␥ of 1.9. This applies to the rare alleles Power estimated for a range of allele frequencies. Power = (1 − ␤) where ␤ = probability of producing a type II error.
A P-value of 0.05 was used to determine significance. A multiplicative mode of inheritance is used in this example: heterozygous genotypic risk ratio (GRR1) = ␥; homozygous genotypic risk ratio (GRR2) = ␥ 2 .
at DBH and DRD2. For alleles with a frequency of 25-50%, the sample had the same power of detecting a ␥ of 1.6-1.7. This applies to COMT, DRD3, the common alleles at DAT1 and the most common allele at DRD5.
Results
The results are presented in Tables 3-8 . Parental genotypes were consistent with Hardy-Weinberg equilibrium and are reported in each table. For each polymorphism we present the overall multiallele TDT statistic and the 2 for the transmission of each individual allele (for biallelic markers the two 2 results are identical). The 'control' allele frequencies represent the nontransmitted parental alleles. None of the overall TDT results was significant and only one individual allele showed a weak trend for being preferentially transmitted (see under DRD5).
DBH (Table 3)
The allele frequencies for the rare S allele in patients and the artificially constructed 'control' population were 8% and 11% respectively. The results from the TDT analysis did not approach conventional levels of statistical significance: 2 = 1.0, 1 df, P = 0.31.
DAT1 (Table 4)
We observed the common alleles of nine and 10 copies of the repeat and only one of the rare alleles: the 11 copies allele which occurred in only one family. Our sample showed no evidence of preferential transmission of these alleles with an overall 2 = 1.67, 2 df, P = 0.43. Table 5 ) and DRD2 (Table 6 ) There was no trend towards preferential transmission of the alleles.
COMT (
DRD3 (Table 7)
Neither allele was preferentially transmitted. As the evidence in the literature points to an increased frequency of homozygosity of either allele in schizophrenic patients, we constructed genotypes with the non-transmitted alleles (the 'control' population) for each family. The frequencies were not significantly different ( 2 = 0.27, 1 df, P = 0.6), but the rate of homozygosity was 3.3% higher in the patient sample.
DRD5 (Table 8)
The overall TDT was not significant: 2 = 14.0, df = 12, P = 0.3. There was evidence for preferential transmission of the most common allele (allele 8) which approached conventional levels of statistical significance on its own (P = 0.05) without controlling for multiple testing.
Discussion
There have been both positive and negative linkage and association studies between BP and the genes examined here. The few studies that have employed the TDT have generally used smaller samples than in the current study.
DBH Linkage studies have provided no evidence for linkage between BP and DBH. [35] [36] [37] The polymorphism examined by us was described only recently 16 and we are not aware of any published association studies at the time of submitting this article. Our results do not provide evidence that this functional variant increases susceptibility to BP.
DAT1
Linkage to DAT (at chromosome 5p15.3) has been examined in a set of 21 North American families, three large Icelandic pedigrees and the Old Order Amish pedigree 110. 38 Suggestive evidence for linkage to this region (lod score of 2.38) was obtained in one of these families. In addition to traditional lod score analysis, this study also used the TDT and found modest evidence for association with the DAT1, however association with alleles at the VNTR that we examined reached only a P-value of 0.08 in that study. Case-control association studies between alleles at the DAT1 and bipolar disorder have been both positive 39, 40 and negative. 41, 42 Our results are negative but in view of some of the positive studies, further research on polymorphisms at this gene is justified. COMT Previous association studies between BP and this COMT polymorphism have been negative. A large collaborative case-control association study on 412 BPI patients and 368 controls demonstrated that variation at this functional polymorphism does not make an important contribution to susceptibility to BP in the Western European population, 43 and other groups similarly reported no association between COMT alleles and BP patients from the USA 44 and Spain. 45 The only positive report is on patients from China.
46 = 0.15, P = 0.7. In addition to allele and genotype frequencies we examined the frequency of homozygosity 1/1 + 2/2 and heterozygosity, 1/2 genotype in probands and in the artificially constructed 'control' subjects. The result was not significant: 2 = 0.27, P = 0.6. Our results are in line with the predominantly negative reports on this polymorphism. There is, however a possibility that the low-activity allele might modify the course of BP by inducing a rapid cycling form of the illness, as we 32 and others 47 have suggested.
DRD2
Linkage to markers around DRD2 has been excluded in several studies. 37,48-52 Arinami et al 21 found that the rare −141Del allele at the DRD2 promoter region had a significantly lower frequency in schizophrenic patients. No association with the DRD2 Ins/Del allele was found in two studies on BP patients. 53, 54 Our results are consistent with these negative findings.
DRD3
Most of the interest in this gene has come from studies in schizophrenia. A meta-analysis of over 30 studies of association between schizophrenia and the DRD3 polymorphism found an excess of both forms of homozygote in patients (P = 0.0009) in a combined sample of 5351 individuals. 22 There have been far fewer studies in BP and their results have been negative. Linkage to DRD3 was excluded in two studies. 37, 55 An increased transmission of allele 1 in bipolar families has been reported 56 but not in another study using the TDT. 57 Association with the DRD3 gene was not found in several case-control samples. 39, 41, 42, 55, [58] [59] [60] We found no evidence for either preferential transmission of one of the alleles nor for a significantly higher rate of homozygosity in our sample (P = 0.6). It is possible that the reported effect is present only in schizophrenia, or alternatively, that our sample did not have sufficient power to detect a small difference (an odds ratio of only 1.21 was estimated by Williams et al). 22 Indeed, the sample showed a very small increase (3.3%) in homozygosity compared to the artificially constructed population of non-transmitted alleles.
DRD5
Although our results were negative overall, there was a trend for the most common allele (allele 8) to be preferentially transmitted, which approached statistical significance without correcting for multiple testing. The allele frequencies in patients and controls were 50% and 41.4% respectively. A similar trend was observed previously in a sample of 120 BP patients and 111 controls: 51% and 45%, although those results were not significant either. 25 There have been three positive linkage results involving the area of DRD5 on chromosome 4p. 24, 25, 61 Absence of linkage to this region or to DRD5 has also been reported (for review see Refs 25 and 37).
Summary
Our results for six polymorphisms in genes involved in the dopaminergic system provide no evidence that they increase susceptibility to BP. Our sample had a power of 80% to detect an association which confers a heterozygous relative risk (␥) ranging from 1.6 to 1.9 for alleles of moderate frequency (0.1-0.5). The corresponding homozygous relative risk in a multiplicative mode of inheritance (␥ 2 ) is 2.56-3.61. These are realistic effect sizes showing that the tested polymorphisms do not have a substantial contribution to illness and are not in linkage disequilibrium with other disease-predisposing polymorphisms at these genes. While we attempted to test functional polymorphisms, the DAT1 and DRD5 polymorphisms are likely to be anonymous variants. Our power calculations refer to the situation where the tested marker is the disease marker itself. It has been shown that the power of the TDT can drop dramatically if the tested marker is not in complete (or nearly complete) linkage disequilibrium with the disease locus. 62 In non-isolated populations such as the one investigated by us, linkage disequilibrium can decay substantially even over small genetic distances, so it is conceivable that there are other, as yet unknown variants at the genes tested which contribute to illness but are not in complete disequilibrium with the markers tested in this study. Therefore we cannot exclude the involvement of these genes but only of the polymorphisms tested. The only potentially interesting result is the preferential transmission of allele 8 of DRD5, as a similar trend was noticed in a previous report by our team 25 and the gene maps to an area strongly implicated by linkage studies, as pointed out above.
